Literature DB >> 33574090

YAP and β-Catenin Cooperate to Drive Oncogenesis in Basal Breast Cancer.

Hazel M Quinn1, Regina Vogel1, Oliver Popp1, Philipp Mertins1, Linxiang Lan2,3, Clemens Messerschmidt4,5, Alexandro Landshammer6, Kamil Lisek1, Sophie Château-Joubert7, Elisabetta Marangoni8, Elle Koren9, Yaron Fuchs9, Walter Birchmeier10.   

Abstract

Targeting cancer stem cells (CSC) can serve as an effective approach toward limiting resistance to therapies. While basal-like (triple-negative) breast cancers encompass cells with CSC features, rational therapies remain poorly established. We show here that the receptor tyrosine kinase Met promotes YAP activity in basal-like breast cancer and find enhanced YAP activity within the CSC population. Interfering with YAP activity delayed basal-like cancer formation, prevented luminal to basal transdifferentiation, and reduced CSC. YAP knockout mammary glands revealed a decrease in β-catenin target genes, suggesting that YAP is required for nuclear β-catenin activity. Mechanistically, nuclear YAP interacted with β-catenin and TEAD4 at gene regulatory elements. Proteomic patient data revealed an upregulation of the YAP signature in basal-like breast cancers. Our findings demonstrate that in basal-like breast cancers, β-catenin activity is dependent on YAP signaling and controls the CSC program. These findings suggest that targeting the YAP/TEAD4/β-catenin complex offers a potential therapeutic strategy for eradicating CSCs in basal-like breast cancers. SIGNIFICANCE: These findings show that YAP cooperates with β-catenin in basal-like breast cancer to regulate CSCs and that targeting this interaction may be a novel CSC therapy for patients with basal-like breast cancer. GRAPHICAL ABSTRACT: http://cancerres.aacrjournals.org/content/canres/81/8/2116/F1.large.jpg. ©2021 American Association for Cancer Research.

Entities:  

Year:  2021        PMID: 33574090     DOI: 10.1158/0008-5472.CAN-20-2801

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  9 in total

1.  Dysregulation of the Scribble/YAP/β-catenin axis sustains the fibroinflammatory response in a PKHD1-/- mouse model of congenital hepatic fibrosis.

Authors:  Luca Fabris; Chiara Milani; Romina Fiorotto; Valeria Mariotti; Eleanna Kaffe; Barbara Seller; Aurelio Sonzogni; Mario Strazzabosco; Massimiliano Cadamuro
Journal:  FASEB J       Date:  2022-06       Impact factor: 5.834

2.  Expression of yes-associated protein, β-catenin and smoothened, and their clinical significance in invasive breast cancer.

Authors:  Pengju Liu; Jianfeng Zeng; Gaohua Yang
Journal:  Exp Ther Med       Date:  2022-05-06       Impact factor: 2.751

Review 3.  Epithelial-mesenchymal transition: The history, regulatory mechanism, and cancer therapeutic opportunities.

Authors:  Zhao Huang; Zhe Zhang; Chengwei Zhou; Lin Liu; Canhua Huang
Journal:  MedComm (2020)       Date:  2022-05-18

Review 4.  TEAD4 as an Oncogene and a Mitochondrial Modulator.

Authors:  Sheng-Chieh Hsu; Ching-Yu Lin; Yen-Yi Lin; Colin C Collins; Chia-Lin Chen; Hsing-Jien Kung
Journal:  Front Cell Dev Biol       Date:  2022-05-05

5.  HTLV-1 activates YAP via NF-κB/p65 to promote oncogenesis.

Authors:  Tiejun Zhao; Zhilong Wang; Jinyong Fang; Wenzhao Cheng; Yiling Zhang; Jinhua Huang; Lingling Xu; Hongwei Gou; Linghui Zeng; Zhigang Jin; Masao Matsuoka
Journal:  Proc Natl Acad Sci U S A       Date:  2022-03-01       Impact factor: 12.779

6.  Mechanosensitive Piezo1 is crucial for periosteal stem cell-mediated fracture healing.

Authors:  Yunlu Liu; Hongtao Tian; Yuxiang Hu; Yulin Cao; Hui Song; Shenghui Lan; Zhipeng Dai; Wei Chen; Yingze Zhang; Zengwu Shao; Yong Liu; Wei Tong
Journal:  Int J Biol Sci       Date:  2022-06-13       Impact factor: 10.750

Review 7.  Advances in Biomarkers and Endogenous Regulation of Breast Cancer Stem Cells.

Authors:  Wenmin Chen; Lu Zhang; Suling Liu; Ceshi Chen
Journal:  Cells       Date:  2022-09-20       Impact factor: 7.666

Review 8.  Signaling pathways in the regulation of cancer stem cells and associated targeted therapy.

Authors:  Wang Manni; Wu Min
Journal:  MedComm (2020)       Date:  2022-10-05

9.  RICH1 inhibits breast cancer stem cell traits through activating kinases cascade of Hippo signaling by competing with Merlin for binding to Amot-p80.

Authors:  Qi Tian; Huan Gao; Yan Zhou; Lizhe Zhu; Jiao Yang; Bo Wang; Peijun Liu; Jin Yang
Journal:  Cell Death Dis       Date:  2022-01-21       Impact factor: 9.685

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.